The biotech and pharma sector is at a crossroads, propelled by game-changing technologies yet battered by unprecedented challenges. Cutting-edge gene editing tools like CRISPR, AI-powered drug discovery, and RNA-based therapies are revolutionizing treatments for cancer, autoimmune disorders, and rare diseases. Yet, a storm of obstacles looms: shifting trade policies, crippling tariff hikes, and supply chain crises—especially for active pharmaceutical ingredients (APIs)—are skyrocketing costs and jeopardizing access. Beyond relentless regulatory hurdles that delay approvals and inflate compliance costs, U.S. startups and established firms alike face soaring R&D expenses, high failure rates, and a looming innovation threat from proposed $100,000 H-1B visa fees that choke access to global talent.
To navigate this high-stakes landscape, Mizuho Americas analyst Graig Suvannavejh will reveal what’s sizzling and what’s fizzling in the healthcare sector he covers. Jim Bruno, a seasoned APIs consultant, will dissect supply chain chaos. And Adam Closson of Chemical Angels will spotlight startups poised to dominate with breakthrough technologies and unpack the daunting barriers they face.
FREE ACCESS FOR LIMITIED TIME!
Video link will be emailed within 48 hours of purchase